Literature DB >> 15364915

Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion.

Yuko Kawakami1, Hajime Nishimoto, Jiro Kitaura, Mari Maeda-Yamamoto, Roberta M Kato, Dan R Littman, Michael Leitges, David J Rawlings, Toshiaki Kawakami.   

Abstract

Akt (= protein kinase B), a subfamily of the AGC serine/threonine kinases, plays critical roles in survival, proliferation, glucose metabolism, and other cellular functions. Akt activation requires the recruitment of the enzyme to the plasma membrane by interacting with membrane-bound lipid products of phosphatidylinositol 3-kinase. Membrane-bound Akt is then phosphorylated at two sites for its full activation; Thr-308 in the activation loop of the kinase domain is phosphorylated by 3-phosphoinositide-dependent kinase-1 (PDK1) and Ser-473 in the C-terminal hydrophobic motif by a putative kinase PDK2. The identity of PDK2 has been elusive. Here we present evidence that conventional isoforms of protein kinase C (PKC), particularly PKCbetaII, can regulate Akt activity by directly phosphorylating Ser-473 in vitro and in IgE/antigen-stimulated mast cells. By contrast, PKCbeta is not required for Ser-473 phosphorylation in mast cells stimulated with stem cell factor or interleukin-3, in serum-stimulated fibroblasts, or in antigen receptor-stimulated T or B lymphocytes. Therefore, PKCbetaII appears to work as a cell type- and stimulus-specific PDK2.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364915     DOI: 10.1074/jbc.M408797200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

Review 1.  Low-level laser therapy: a useful technique for enhancing the proliferation of various cultured cells.

Authors:  Khalid M AlGhamdi; Ashok Kumar; Noura A Moussa
Journal:  Lasers Med Sci       Date:  2011-01-28       Impact factor: 3.161

2.  Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1.

Authors:  Jonathan Brown; Huizhi Wang; Jill Suttles; Dana T Graves; Michael Martin
Journal:  J Biol Chem       Date:  2011-11-01       Impact factor: 5.157

3.  Akt isoforms differentially regulate neutrophil functions.

Authors:  Jia Chen; Haiyang Tang; Nissim Hay; Jingsong Xu; Richard D Ye
Journal:  Blood       Date:  2010-03-23       Impact factor: 22.113

Review 4.  Specific protein kinase C isoforms as transducers and modulators of insulin signaling.

Authors:  Sanford R Sampson; Denise R Cooper
Journal:  Mol Genet Metab       Date:  2006-06-23       Impact factor: 4.797

5.  Age-associated impairment of Akt phosphorylation in primary rat hepatocytes is remediated by alpha-lipoic acid through PI3 kinase, PTEN, and PP2A.

Authors:  Kate Petersen Shay; Tory M Hagen
Journal:  Biogerontology       Date:  2008-10-18       Impact factor: 4.277

6.  Akt signaling in platelets and thrombosis.

Authors:  Donna S Woulfe
Journal:  Expert Rev Hematol       Date:  2010-02       Impact factor: 2.929

7.  Growth hormone modulation of EGF-induced PI3K-Akt pathway in mice liver.

Authors:  Ma Eugenia Díaz; Lorena González; Johanna G Miquet; Carolina S Martínez; Ana I Sotelo; Andrzej Bartke; Daniel Turyn
Journal:  Cell Signal       Date:  2011-10-14       Impact factor: 4.315

8.  Akt-PDK1 complex mediates epidermal growth factor-induced membrane protrusion through Ral activation.

Authors:  Hisayoshi Yoshizaki; Naoki Mochizuki; Yukiko Gotoh; Michiyuki Matsuda
Journal:  Mol Biol Cell       Date:  2006-11-01       Impact factor: 4.138

9.  PKCdelta survival signaling in cells containing an activated p21Ras protein requires PDK1.

Authors:  Shuhua Xia; Zhihong Chen; Lora W Forman; Douglas V Faller
Journal:  Cell Signal       Date:  2008-12-10       Impact factor: 4.315

10.  AKT regulates BRCA1 stability in response to hormone signaling.

Authors:  Andrew C Nelson; Traci R Lyons; Christian D Young; Kirk C Hansen; Steven M Anderson; Jeffrey T Holt
Journal:  Mol Cell Endocrinol       Date:  2010-01-18       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.